Suppr超能文献

使用迪厄多内标准的治疗后PET/CT而非中期PET/CT可预测儿童霍奇金淋巴瘤的预后:一项比较PET/CT与传统成像的前瞻性研究

Posttreatment PET/CT Rather Than Interim PET/CT Using Deauville Criteria Predicts Outcome in Pediatric Hodgkin Lymphoma: A Prospective Study Comparing PET/CT with Conventional Imaging.

作者信息

Bakhshi Sameer, Bhethanabhotla Sainath, Kumar Rakesh, Agarwal Krishankant, Sharma Punit, Thulkar Sanjay, Malhotra Arun, Dhawan Deepa, Vishnubhatla Sreenivas

机构信息

Department of Medical Oncology, Dr. B. R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India

Department of Medical Oncology, Dr. B. R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India.

出版信息

J Nucl Med. 2017 Apr;58(4):577-583. doi: 10.2967/jnumed.116.176511. Epub 2016 Oct 6.

Abstract

Data about the significance of F-FDG PET at interim assessment and end of treatment in pediatric Hodgkin lymphoma (HL) are limited. Patients (≤18 y) with HL were prospectively evaluated with contrast-enhanced CT (CECT) and PET combined with low-dose CT (PET/CT) at baseline, after 2 cycles of chemotherapy, and after completion of treatment. Revised International Working Group (RIW) criteria and Deauville 5 point-scale for response assessment by PET/CT were used. All patients received doxorubicin (Adriamycin), bleomycin, vinblastine, dacarbazine chemotherapy along with involved-field radiotherapy (25 Gy) for early stage (IA, IB, and IIA) and advanced stage (IIB-IV) with bulky disease. Of the 57 enrolled patients, median follow-up was 81.6 mo (range, 11-97.5 mo). Treatment decisions were based on CECT. At baseline, PET/CT versus CECT identified 67 more disease sites; 23 patients (40.3%) were upstaged and of them in 9 patients (39%) upstaging would have affected treatment decision; notably none of these patients relapsed. The specificity of interim PET/CT based on RIW criteria (61.5%) and Deauville criteria (91.4%) for predicting relapse was higher than CECT (40.3%) ( = 0.03 and < 0.0001, respectively). Event-free survival based on interim PET/CT (RIW) response was 93.3 ± 4.1 versus 89.6 ± 3.8 (positive vs. negative scan, respectively; = 0.44). The specificity of posttreatment PET/CT (Deauville) was 95.7% versus 76.4% by CECT ( = 0.006). Posttreatment PET/CT (Deauville) showed significantly inferior overall survival in patients with positive scan versus negative scan results (66.4 ± 22.5 vs. 94.5 ± 2.0, = 0.029). Interim PET/CT has better specificity, and use of Deauville criteria further improves it. Escalation of therapy based on interim PET in pediatric HL needs further conclusive evidence to justify its use. Posttreatment PET/CT (Deauville) predicts overall survival and has better specificity in comparison to conventional imaging.

摘要

关于氟代脱氧葡萄糖正电子发射断层扫描(F-FDG PET)在儿童霍奇金淋巴瘤(HL)中期评估及治疗结束时的意义的数据有限。对HL患者(≤18岁)在基线、化疗2个周期后及治疗结束时进行前瞻性评估,采用对比增强CT(CECT)以及PET联合低剂量CT(PET/CT)检查。采用修订的国际工作组(RIW)标准和Deauville 5分制对PET/CT检查结果进行疗效评估。所有患者均接受多柔比星(阿霉素)、博来霉素、长春花碱、达卡巴嗪化疗,并对早期(IA、IB和IIA期)和伴有大包块病变的晚期(IIB-IV期)患者进行受累野放疗(25 Gy)。在纳入的57例患者中,中位随访时间为81.6个月(范围11 - 97.5个月)。治疗决策基于CECT结果。在基线时,PET/CT与CECT相比多发现67个病变部位;23例患者(40.3%)分期上调,其中9例患者(39%)分期上调会影响治疗决策;值得注意的是,这些患者均未复发。基于RIW标准(61.5%)和Deauville标准(91.4%)的中期PET/CT预测复发的特异性高于CECT(40.3%)(分别为P = 0.03和P < 0.0001)。基于中期PET/CT(RIW)反应的无事件生存率为93.3±4.1,而CECT为89.6±3.8(扫描阳性与阴性分别对比;P = 0.44)。治疗后PET/CT(Deauville)的特异性为95.7%,而CECT为76.4%(P = 0.006)。治疗后PET/CT(Deauville)显示扫描阳性患者的总生存率显著低于扫描阴性患者(66.4±22.5对94.5±2.0,P = 0.029)。中期PET/CT具有更好的特异性,采用Deauville标准可进一步提高其特异性。基于儿童HL中期PET结果进行治疗强化需要进一步的确凿证据来证明其合理性。治疗后PET/CT(Deauville)可预测总生存率,且与传统影像学相比具有更好的特异性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验